Pramipexole Dihydrochloride Tablets, 0.25 mg, 90-count tablets per bottle, Rx only, Manufactured ...

FDA Drug Recall #D-1677-2012 — Class III — September 12, 2012

Recall Summary

Recall Number D-1677-2012
Classification Class III — Low risk
Date Initiated September 12, 2012
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Sandoz Incorporated
Location Broomfield, CO
Product Type Drugs
Quantity 43,060 x 90 count bottles

Product Description

Pramipexole Dihydrochloride Tablets, 0.25 mg, 90-count tablets per bottle, Rx only, Manufactured in India by Sandoz Private Ltd., for Sandoz Inc., Princeton, NJ 08540, NDC 0781- 5249-92,

Reason for Recall

Impurities/Degradation Products: An out of specification result for a known impurity of the product occurred during 12 month stability testing.

Distribution Pattern

Nationwide

Lot / Code Information

Lot numbers: BJ3338; BJ3339; BJ 3340; BJ3341; BJ3342; BJ6282; BJ7192; BM8498; BJ7202; BJ7203, Exp 12/12

Other Recalls from Sandoz Incorporated

Recall # Classification Product Date
D-0631-2018 Class III Triamterene and Hydrochlorothiazide Tablets, US... Apr 6, 2018
D-0943-2017 Class III Amitriptyline HCl Tablets, USP 25 mg, Packaged ... Jun 16, 2017
D-0236-2017 Class II Nadolol Tablets, USP, 40mg, packaged in 1000-co... Dec 22, 2016
D-0291-2015 Class III Fluoxetine Capsules USP, 20 mg, 100 count bottl... Dec 5, 2014
D-1509-2014 Class II Alprazolam Tablets, USP, 0.25mg, Rx only, 1000 ... Jul 25, 2014

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.